Retham Technologies (Milwaukee) is a diagnostics company developing an in vitro diagnostic assay for the diagnosis of Heparin-induced thrombocytopenia (HIT), a disease which kills five people per day in the United States. Retham developed a method of stabilizing platelets for at least one year, whereas platelets typically live only a few days.
Retham was cofounded by Dr. Anand Padmanabhan and Daniel Sem in 2017, based on groundbreaking research Dr. Padmanabhan conducted when he was at Blood Center of Wisconsin. The clinical diagnostic assay the company is developing provides more reliable results in less time (< 1 day vs. 3 days) than the current market-dominant test for HIT, and will prevent many deaths or amputations from this autoimmune reaction that nearly 1% of patients have to Heparin treatment. Retham expects its HITDx assay to be on the market and in clinical labs by 2023.